ACM
AMAG

AlphaCrest Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

AlphaCrest Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,800
Closed -$108K – 1385
2019
Q2 		$108K Buy
+10,800
New +$117K 0.01% 993

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AlphaCrest Capital Management's AMAG Position: Q3 2019 in Review

AlphaCrest Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q3 2019, closing a stake of 10,800 shares — an estimated $108K sold.

AlphaCrest Capital Management first reported a position in AMAG in Q2 2019 and held it in 1 quarter. The position peaked at $108K in Q2 2019. 156 funds tracked by Wall St. Rank hold AMAG as of Q3 2019.

  • AlphaCrest Capital Management reported no remaining AMAG Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • AlphaCrest Capital Management sold 10,800 AMAG Pharmaceuticals shares in Q3 2019, an estimated $108K.
  • AlphaCrest Capital Management first reported a position in AMAG Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • AlphaCrest Capital Management's AMAG Pharmaceuticals position peaked at $108K in Q2 2019.
  • 156 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2019.

Based on AlphaCrest Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.